Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0847097 (acidity)
 15,165 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Acidogenic function of the stomach and role of gastroesophageal reflux were assessed in relation to esophagitis genesis in 92 patients with portal hypertension and varicosity of the stomach and esophagus. Acidogenic function was found heterogenous. The relationship between gastric acidity, gastroesophageal reflux and esophagitis development seemed obscure, whereas that between esophageal varicosity of a definite degree and esophagitis was clear-cut.
 ...
PMID:[Pathogenesis of esophagitis in patients with portal hypertension]. 233 33

The gastric juice acidity was analyzed in 6 healthy children and 46 children with different diseases of the liver and portal system. The method of fractional intubation or acidotest was used. It was established that the drop of the stimulated gastric secretion in patients with chronic diseases of the liver was dependent on the degree of the hepatocyte lesion rather than on the concomitant portal hypertension. In the extrahepatic blockade of the portal blood circulation the gastric juice secretion was either normal or high. A relationship was found between the activity of the stimulated gastric juice secretion and gastro-esophageal hemorrhages. Splenectomy resulted in higher stimulated gastric secretion while the Tanner operation distinctly inhibited it for a long period (up to 3 years).
 ...
PMID:[Acid-forming function of the stomach in liver diseases and extrahepatic blockade of the portal circulation in children before and after surgical treatment]. 736 84

Human epidermal growth factor (EGF), a small polypeptide (6 kDa) with mitogenic properties, has been implicated in the protection of gastrointestinal mucosal integrity. The efficacy of EGF in the prevention and healing of sclerotherapy-induced esophageal lesions was investigated in 24 minipigs with surgically induced portal hypertension. In addition, the effect of EGF on intragastric acidity and pharmacokinetics was investigated as possible means to explain its protective mechanism of action. The animals underwent three weekly sessions of sclerotherapy with polidocanol 2% and were concomitantly and for an additional three weeks treated with either placebo or EGF administered paravenously in the esophagus and/or subcutaneously. The subcutaneous treatment with EGF significantly (P < 0.05) reduced esophageal stricture and scar formations associated with sclerotherapy. Gastric pH values were significantly (P < 0.01) elevated only in animals receiving subcutaneous injections of EGF. Furthermore, the subcutaneous administration of EGF was associated with unexpected prolonged plasma concentration of the peptide. These results suggest a possible clinical value of EGF as an adjunctive treatment with the sclerotherapy.
 ...
PMID:Systemic treatment with recombinant human epidermal growth factor accelerates healing of sclerotherapy-induced esophageal ulcers and prevents esophageal stricture formations in pigs. 799 95